This application seeks support for the activities of the Eastern Cooperative Oncology Group (ECOG) at the University of Wisconsin Comprehensive Cancer Center (UWCCC) and affiliated institutions. The clinical programs of the UWCCC are designed to improve both the treatment and care of cancer patients as well as to reduce the burden of the cancer problem in general. Our long association with the Eastern Cooperative Oncology Group (ECOG) has been beneficial in enhancing these goals. ? ? UWCCC Investigators have a history of strong commitment to ECOG accrual as well as administrative and scientific leadership. UWCCC clinics are organized along disease specific lines with efforts to enhance the multidisciplinary approaches needed for today's optimal cancer care and clinical research. During the last grant cycle this approach has been strengthened with recruitment in Medical Oncology and Surgery, new clinic space and enhancement of computerized research database facilities. All of this has improved our ECOG effort as manifested by consistent high accrual and group leadership activities. UW investigators chair the GU and Thoracic committees and co-chair the Pharmacology committee. UW investigators will lead chemoprevention efforts in ECOG. ? ? Institutional evaluations consistently rank the UW ECOG program at or near the top in categories of accrual, administrative and scientific leadership. UW ECOG affiliates continue to contribute with significant accrual and high quality data management and rank among the best in ECOG. ECOG studies and a clinical trials approach in cancer care are essential for continued high quality in the cancer programs at UW and throughout the region. ECOG studies serve as a core curriculum for trainees in Hematology and Medical and Radiation Oncology and as a basis for clinical strategies. The ECOG program remains an important component of the UWCCC cancer research effort and UWCCC contributions to ECOG remain equally important to the Group. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA021076-32
Application #
7257228
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
1978-06-01
Project End
2010-04-30
Budget Start
2007-05-01
Budget End
2008-04-30
Support Year
32
Fiscal Year
2007
Total Cost
$588,460
Indirect Cost
Name
University of Wisconsin Madison
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
161202122
City
Madison
State
WI
Country
United States
Zip Code
53715
Lubner, Sam; Feng, Yang; Mulcahy, Mary et al. (2018) E4206: AMG 706 and Octreotide in Patients with Low-Grade Neuroendocrine Tumors. Oncologist 23:1006-e104
Moots, Paul L; O'Neill, Anne; Londer, Harold et al. (2018) Preradiation Chemotherapy for Adult High-risk Medulloblastoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4397). Am J Clin Oncol 41:588-594
Gravis, Gwenaelle; Boher, Jean-Marie; Chen, Yu-Hui et al. (2018) Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies. Eur Urol 73:847-855
Erbe, Amy K; Wang, Wei; Goldberg, Jacob et al. (2017) FCGR Polymorphisms Influence Response to IL2 in Metastatic Renal Cell Carcinoma. Clin Cancer Res 23:2159-2168
Smith, M R; Hong, F; Li, H et al. (2017) Mantle cell lymphoma initial therapy with abbreviated R-CHOP followed by 90Y-ibritumomab tiuxetan: 10-year follow-up of the phase 2 ECOG-ACRIN study E1499. Leukemia 31:517-519
Agarwala, Sanjiv S; Lee, Sandra J; Yip, Waiki et al. (2017) Phase III Randomized Study of 4 Weeks of High-Dose Interferon-?-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Gro J Clin Oncol 35:885-892
Perez Horta, Zulmarie; Goldberg, Jacob L; Sondel, Paul M (2016) Anti-GD2 mAbs and next-generation mAb-based agents for cancer therapy. Immunotherapy 8:1097-117
Haas, Naomi B; Manola, Judith; Uzzo, Robert G et al. (2016) Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 387:2008-16
Wang, Wei; Erbe, Amy K; Gallenberger, Mikayla et al. (2016) Killer immunoglobulin-like receptor (KIR) and KIR-ligand genotype do not correlate with clinical outcome of renal cell carcinoma patients receiving high-dose IL2. Cancer Immunol Immunother 65:1523-1532
Barta, Stefan K; Li, Hailun; Hochster, Howard S et al. (2016) Randomized phase 3 study in low-grade lymphoma comparing maintenance anti-CD20 antibody with observation after induction therapy: A trial of the ECOG-ACRIN Cancer Research Group (E1496). Cancer 122:2996-3004

Showing the most recent 10 out of 181 publications